LORAZEPAM INJECTION USP SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

LORAZEPAM

Verfügbar ab:

PFIZER CANADA ULC

ATC-Code:

N05BA06

INN (Internationale Bezeichnung):

LORAZEPAM

Dosierung:

4MG

Darreichungsform:

SOLUTION

Zusammensetzung:

LORAZEPAM 4MG

Verabreichungsweg:

INTRAMUSCULAR

Einheiten im Paket:

1ML

Verschreibungstyp:

Targeted (CDSA IV)

Therapiebereich:

BENZODIAZEPINES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0110731004; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2017-09-07

Fachinformation

_Product Monograph - Lorazepam Injection USP_
_Page 1 of 30 _
PRODUCT MONOGRAPH
LORAZEPAM INJECTION USP
(lorazepam)
Sterile Solution
4 mg/mL
Anxiolytic – Sedative
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5
Submission Control No.: 230606
Date of Revision:
August 22, 2019
_ _
_Product Monograph - Lorazepam Injection USP_
_Page 2 of 30 _
TABLE OF CONTENTS
ACTION
..............................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS
........................................................................................................................4
PRECAUTIONS
..................................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
ADVERSE REACTIONS
..................................................................................................10
OVERDOSAGE
................................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
STORAGE AND STABILITY
..........................................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................16
DETAILED PHARMACOLOGY
.....................................................................................17
TOXICOLOGY
.................................................................................................................19
REFERENCES
...............